(Q51166879)

31 March 2018

title

Biodistribution and pharmacokinetics of dapivirine-loaded nanoparticles after vaginal delivery in mice. (English)

1 reference

31 March 2018

0 references

1 reference

1

1 reference

31 March 2018

Fernanda Andrade

3

1 reference

31 March 2018

Bruno Sarmento

6

1 reference

31 March 2018

Francisca Araújo

object named as

Francisca Araújo

2

0 references

author name string

Mansoor Amiji

4

1 reference

31 March 2018

Maria Fernanda Bahia

5

1 reference

31 March 2018

publication date

22 January 2014

1 reference

31 March 2018

published in

Pharmaceutical Research

1 reference

31 March 2018

volume

31

1 reference

31 March 2018

issue

7

1 reference

31 March 2018

page(s)

1834-1845

1 reference

31 March 2018

Systemic and topical drugs for the prevention of HIV infection: antiretroviral pre-exposure prophylaxis

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Overview of microbicides for the prevention of human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Concentrations of dapivirine in the rhesus macaque and rabbit following once daily intravaginal administration of a gel formulation of [14C]dapivirine for 7 days.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. Hydroxyethyl cellulose-based universal placebo gel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Delivery of microbicides to the vagina: difficulties reported with the use of three devices, adherence to use and preferences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Nanotechnology-based systems for the treatment and prevention of HIV/AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Nanoparticle-based vaginal drug delivery systems for HIV prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Interactions of microbicide nanoparticles with a simulated vaginal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

In vitro and ex vivo evaluation of polymeric nanoparticles for vaginal and rectal delivery of the anti-HIV drug dapivirine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Development and validation of a rapid reversed-phase HPLC method for the determination of the non-nucleoside reverse transcriptase inhibitor dapivirine from polymeric nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Effects of menstrual cycle on gene transfection through mouse vagina for DNA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Ex vivo characterization of particle transport in mucus secretions coating freshly excised mucosal tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Development and validation of a HPLC method for the assay of dapivirine in cell-based and tissue permeability experiments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Assessing the physical-chemical properties and stability of dapivirine-loaded polymeric nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Setting the stage: host invasion by HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Controlled surface modification with poly(ethylene)glycol enhances diffusion of PLGA nanoparticles in human cervical mucus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Mucoadhesive nanosystems for vaginal microbicide development: friend or foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Biodegradable nanoparticles in the murine vagina: trans-cervical retrograde transport and induction of proinflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Formulation, pharmacokinetics and pharmacodynamics of topical microbicides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Effect of carrageenan on poloxamer-based in situ gel for vaginal use: Improved in vitro and in vivo sustained-release properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Pharmacokinetics and pharmacodynamics in HIV prevention; current status and future directions: a summary of the DAIDS and BMGF sponsored think tank on pharmacokinetics (PK)/pharmacodynamics (PD) in HIV prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Animal models for microbicide studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Polymeric Nanoparticles Affect the Intracellular Delivery, Antiretroviral Activity and Cytotoxicity of the Microbicide Drug Candidate Dapivirine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Pharmacokinetic Assessment of Dapivirine Vaginal Microbicide Gel in Healthy, HIV-Negative Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Safety and Availability of Dapivirine (TMC120) Delivered from an Intravaginal Ring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1287-X

Residence half-life of IgG administered topically to the mouse vagina

21 January 2018

1 reference

12 December 2020

Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women

1 reference

12 December 2020

Physiological parameters in laboratory animals and humans

1 reference

12 December 2020

Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation

1 reference

12 December 2020

Targeted drug delivery in gynaecology: the first uterine pass effect

1 reference

12 December 2020

10.1007/S11095-013-1287-X

Identifiers

DOI

1 reference

31 March 2018

PubMed ID

24449442

1 reference

31 March 2018